Abstract
Zn(II) is an inhibitor of SARS-CoV-2′s RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores–this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics.
Author supplied keywords
Cite
CITATION STYLE
Hecel, A., Ostrowska, M., Stokowa-Sołtys, K., Wątły, J., Dudek, D., Miller, A., … Rowińska-żyrek, M. (2020). Zinc(Ii)—the overlooked Éminence grise of chloroquine’s fight against covid-19? Pharmaceuticals, 13(9), 1–29. https://doi.org/10.3390/ph13090228
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.